Clinical Trial Update: Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 2 study of zanubrutinib plus GCVP (obinutuzumab, cyclophosphamide, vindesine, prednisolone) in previously untreated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Obinutuzumab (obinutuzumab)
• Prednisolone (Prednisolone)
• Vindesine (vindesine)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: BTK Inhibitors, Follicular Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING